Page 3 - Nir Hacohen News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Share This The FINANCIAL -- Researchers at Harvard-affiliated Massachusetts General Hospital (MGH) have identified the protein “signature” of severe COVID-19, which they describe in a new study published in Cell Reports Medicine. “We were interested in asking whether we could identify mechanisms that might be contributing to death in COVID-19,” says MGH infectious disease expert Marcia Goldberg, who studies interactions between microbial pathogens and their hosts, and is senior author of the study. “In other words, why do some patients die from this disease, while others — who a...

Researchers at Massachusetts General Hospital have identified the protein "signature" of severe COVID-19, which they describe in a new study published in Cell Reports Medicine.

 E-Mail BOSTON - Researchers at Massachusetts General Hospital (MGH) have identified the protein "signature" of severe COVID-19, which they describe in a new study published in Cell Reports Medicine. "We were interested in asking whether we could identify mechanisms that might be contributing to death in COVID-19," says MGH infectious disease expert Marcia Goldberg, MD, who studies interactions between microbial pathogens and their hosts, and is senior author of the study. "In other words, why do some patients die from this disease, while others--who appear to be just as ill--survive?" In ...

Harvard Medical School This article is part of Harvard Medical School’s continuing coverage of medicine, biomedical research, medical education, and policy related to the SARS-CoV-2 pandemic and the disease COVID-19. By TIM GOWER | MGH News and Public Affairs Harvard Medical School researchers at Massachusetts General Hospital have identified the protein “signature” of severe COVID-19, which they describe in a new study published in Cell Reports Medicine. “We were interested in asking whether we could identify mechanisms that might be contributing to death in COVI...

Date Time Personalized vaccine produces long-lasting anti-tumor response in patients with melanoma, study shows Four years after patients with melanoma were treated with a personalized cancer vaccine, the immune response kindled by the vaccine remains robust and effective in keeping cancer cells under control, researchers at Dana-Farber Cancer Institute, Brigham and Women’s Hospital, and the Broad Institute of MIT and Harvard report in a new study. The findings, published online today by the journal Nature Medicine, demonstrate the staying power of the immune response generated by the vacci...